Board Member
Rigel Pharmaceuticals Inc (RIGL)Equibles does not estimate personal net worth.
Get an email with a short summary when Rigel Pharmaceuticals Inc publishes a filing, an earnings call transcript or a press release.
Get RIGL alertsRaul Rodriguez is recorded as Board Member and CEO at Rigel Pharmaceuticals Inc (RIGL). The newest filing on record that lists Raul Rodriguez as Board Member and CEO at Rigel Pharmaceuticals Inc (RIGL) is dated April 3, 2026. Rigel Pharmaceuticals Inc reported in an 8-K filed May 20, 2026 that Raul Rodriguez was appointed Director, effective May 14, 2026. The proxy statement of Rigel Pharmaceuticals Inc reports total compensation of $2,998,688 for Raul Rodriguez in fiscal 2024, including a base salary of $757,000. Disclosed compensation is on record for 7 fiscal years. Raul Rodriguez has spoken on 27 earnings calls and 2 other investor events across 1 company, most recently for Rigel Pharmaceuticals Inc on November 5, 2026. Rigel Pharmaceuticals Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Rigel Pharmaceuticals Inc includes Raul R. Rodriguez (CEO and Board Member), Dean Schorno (CFO), Raymond Furey (General Counsel) and 7 others.
“Each of the nominees for director, to serve until the Company's 2029 Annual Meeting of Stockholders or until his or her respective successor has been elected and qualified, was elected as follows:”
“Also joining me on the call are Dave Santos, our Chief Commercial Officer, Dr. Alison Hanna, our Chief Medical Officer, and Dean Chornu, our Chief Financial Officer.”
“Also with me today are Dave Santos, our Chief Commercial Officer, and Dean Shorno, our Chief Financial Officer. I would also like to welcome Dr. Allison Hanno, our newly appointed Chief Medical Officer, who is with us today and will discuss our development pipeline.”
“Let me start by saying I'd like to take you on this presentation and share with you Rigel's transformational growth strategy. This growth strategy has four interlocking strategic objectives.”
“Also with me today are Dave Santos, our Chief Commercial Officer, and Lisa Royker, our Chief Medical Officer. Joel Asaga, our Chief Business Officer, and Dean Shornow, our Chief Financial Officer, are also here today, and they will be available during our Q&A portion of the call.”
“Also joining me on the call today are Dave Santos, our Chief Commercial Officer, Lisa Royker, our Chief Medical Officer, and Dean Shorno, our Chief Financial Officer.”
Start not stated–present
Last confirmed April 3, 2026
Start not stated–present
Last confirmed April 3, 2026
Biotechnology · Healthcare
Board Member, CEO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Rigel Pharmaceuticals Inc (RIGL) | President and Chief Executive Officer | $757,000 | $2,998,688 |
| 2023 | Rigel Pharmaceuticals Inc (RIGL) | President and Chief Executive Officer | $728,000 | $3,440,790 |
| 2022 | Rigel Pharmaceuticals Inc (RIGL) | President and Chief Executive Officer | $700,000 | $2,864,120 |
| 2020 | Rigel Pharmaceuticals Inc (RIGL) | President and Chief Executive Officer | $662,256 | $2,963,884 |
| 2019 | Rigel Pharmaceuticals Inc (RIGL) | President and Chief Executive Officer | $649,271 | $2,562,118 |
| 2018 | Rigel Pharmaceuticals Inc (RIGL) | President and Chief Executive Officer | $636,540 | $3,980,860 |
| 2017 | Rigel Pharmaceuticals Inc (RIGL) | President and Chief Executive Officer | $618,000 | $2,172,790 |
